BR112017007239A2 - inibidor da aurora a cinase, seus usos, e composição farmacêutica". - Google Patents

inibidor da aurora a cinase, seus usos, e composição farmacêutica".

Info

Publication number
BR112017007239A2
BR112017007239A2 BR112017007239A BR112017007239A BR112017007239A2 BR 112017007239 A2 BR112017007239 A2 BR 112017007239A2 BR 112017007239 A BR112017007239 A BR 112017007239A BR 112017007239 A BR112017007239 A BR 112017007239A BR 112017007239 A2 BR112017007239 A2 BR 112017007239A2
Authority
BR
Brazil
Prior art keywords
methyl
fluoro
pharmaceutical composition
kinase inhibitor
aurora kinase
Prior art date
Application number
BR112017007239A
Other languages
English (en)
Other versions
BR112017007239B1 (pt
Inventor
Robert Henry James
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112017007239A2 publication Critical patent/BR112017007239A2/pt
Publication of BR112017007239B1 publication Critical patent/BR112017007239B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção fornece um composto de aminopiridina selecionado do grupo que consiste em: ácido (2s,4s)-1-[(3-cloro-2-fluoro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil] metil]-2-metil-piperidina-4-carboxílico e ácido (2r,4r)-1-[(3-cloro-2-flu-oro-fenil)metil]-4-[[3-fluoro-6-[(5-metil-1h-pirazol-3-il)amino]-2-piridil] metil]-2-metil-piperidina-4-carboxílico, ou um sal farmaceuticamente aceitável destes, que inibe a aurora a e, portanto, pode ser útil no tratamento de câncer.
BR112017007239-4A 2014-11-14 2015-11-06 Inibidor da aurora a cinase, seus usos, e composição farmacêutica". BR112017007239B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462079742P 2014-11-14 2014-11-14
US62/079,742 2014-11-14
PCT/US2015/059390 WO2016077161A1 (en) 2014-11-14 2015-11-06 Aurora a kinase inhibitor

Publications (2)

Publication Number Publication Date
BR112017007239A2 true BR112017007239A2 (pt) 2017-12-19
BR112017007239B1 BR112017007239B1 (pt) 2023-01-31

Family

ID=54697647

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007239-4A BR112017007239B1 (pt) 2014-11-14 2015-11-06 Inibidor da aurora a cinase, seus usos, e composição farmacêutica".

Country Status (41)

Country Link
US (2) US9637474B2 (pt)
EP (2) EP3473619B8 (pt)
JP (1) JP6159029B2 (pt)
KR (1) KR101930182B1 (pt)
CN (1) CN107108567B (pt)
AR (1) AR102463A1 (pt)
AU (1) AU2015347043B2 (pt)
BR (1) BR112017007239B1 (pt)
CA (1) CA2963473C (pt)
CL (1) CL2017001209A1 (pt)
CO (1) CO2017004784A2 (pt)
CR (1) CR20170158A (pt)
CY (2) CY1121334T1 (pt)
DK (2) DK3473619T3 (pt)
DO (1) DOP2017000111A (pt)
EA (1) EA032102B1 (pt)
EC (1) ECSP17029203A (pt)
ES (2) ES2826448T3 (pt)
HR (2) HRP20190324T1 (pt)
HU (2) HUE043759T2 (pt)
IL (1) IL251406B (pt)
JO (1) JO3488B1 (pt)
LT (2) LT3473619T (pt)
ME (1) ME03325B (pt)
MX (1) MX2017006275A (pt)
MY (1) MY188313A (pt)
NZ (1) NZ730771A (pt)
PE (1) PE20170898A1 (pt)
PH (1) PH12017500881A1 (pt)
PL (1) PL3218366T3 (pt)
PT (2) PT3218366T (pt)
RS (2) RS60999B1 (pt)
SG (1) SG11201703394RA (pt)
SI (2) SI3218366T1 (pt)
SV (1) SV2017005418A (pt)
TN (1) TN2017000116A1 (pt)
TR (1) TR201902686T4 (pt)
TW (1) TWI693218B (pt)
UA (1) UA117983C2 (pt)
WO (1) WO2016077161A1 (pt)
ZA (1) ZA201702199B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI813694B (zh) * 2018-05-29 2023-09-01 日商大鵬藥品工業股份有限公司 抗腫瘤劑及腫瘤治療方法
EP3886855A1 (en) * 2018-11-30 2021-10-06 Eli Lilly And Company An aurora a kinase inhibitor for use in the treatment of neuroblastoma
CN112239465A (zh) * 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 极光激酶抑制剂及其用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
JP2024519188A (ja) 2021-05-24 2024-05-08 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 含窒素複素環系化合物、その調製方法及びその医薬的応用
TW202321215A (zh) * 2021-07-28 2023-06-01 大陸商北京加科思新藥研發有限公司 Aurora a 選擇性抑制劑的多晶型及其用途
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1754706A4 (en) * 2004-05-21 2010-08-18 Banyu Pharma Co Ltd SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
ES2531398T3 (es) * 2008-02-22 2015-03-13 Msd Kk Nuevos derivados de aminopiridina que tienen una acción inhibidora selectiva de Aurora A
JP2012521426A (ja) * 2009-03-24 2012-09-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Also Published As

Publication number Publication date
WO2016077161A1 (en) 2016-05-19
CA2963473A1 (en) 2016-05-19
EP3473619B8 (en) 2020-11-04
DK3218366T3 (en) 2019-04-01
MY188313A (en) 2021-11-27
PT3473619T (pt) 2020-11-11
EP3473619B1 (en) 2020-09-09
RS58347B1 (sr) 2019-03-29
TR201902686T4 (tr) 2019-03-21
HUE043759T2 (hu) 2019-09-30
TW201629038A (zh) 2016-08-16
EA201790838A1 (ru) 2017-12-29
KR20170066623A (ko) 2017-06-14
ME03325B (me) 2019-10-20
US10010540B2 (en) 2018-07-03
HRP20190324T1 (hr) 2019-04-19
PH12017500881B1 (en) 2017-11-06
CY1121334T1 (el) 2020-05-29
LT3473619T (lt) 2020-11-10
EP3218366A1 (en) 2017-09-20
JP6159029B2 (ja) 2017-07-05
ES2716732T3 (es) 2019-06-14
NZ730771A (en) 2018-07-27
AR102463A1 (es) 2017-03-01
ZA201702199B (en) 2018-12-19
US20160137628A1 (en) 2016-05-19
CN107108567A (zh) 2017-08-29
BR112017007239B1 (pt) 2023-01-31
LT3218366T (lt) 2019-04-10
US9637474B2 (en) 2017-05-02
PE20170898A1 (es) 2017-07-12
PT3218366T (pt) 2019-04-01
EP3473619A1 (en) 2019-04-24
CL2017001209A1 (es) 2018-01-12
CY1123592T1 (el) 2022-03-24
AU2015347043B2 (en) 2018-03-22
SI3473619T1 (sl) 2020-10-30
CO2017004784A2 (es) 2017-08-31
SI3218366T1 (sl) 2019-02-28
ECSP17029203A (es) 2018-01-31
IL251406B (en) 2019-08-29
SV2017005418A (es) 2018-10-09
DOP2017000111A (es) 2017-06-15
KR101930182B1 (ko) 2018-12-17
CA2963473C (en) 2018-12-18
UA117983C2 (uk) 2018-10-25
CN107108567B (zh) 2020-01-10
DK3473619T3 (da) 2020-09-21
TWI693218B (zh) 2020-05-11
US20170119751A1 (en) 2017-05-04
ES2826448T3 (es) 2021-05-18
TN2017000116A1 (en) 2018-07-04
HUE051530T2 (hu) 2021-03-01
EP3218366B1 (en) 2019-01-09
AU2015347043A1 (en) 2017-05-04
RS60999B1 (sr) 2020-11-30
PH12017500881A1 (en) 2017-11-06
JO3488B1 (ar) 2020-07-05
EA032102B1 (ru) 2019-04-30
SG11201703394RA (en) 2017-05-30
CR20170158A (es) 2017-06-21
IL251406A0 (en) 2017-05-29
MX2017006275A (es) 2017-08-14
HRP20201681T1 (hr) 2020-12-25
JP2016539942A (ja) 2016-12-22
PL3218366T3 (pl) 2019-06-28

Similar Documents

Publication Publication Date Title
BR112017007239A2 (pt) inibidor da aurora a cinase, seus usos, e composição farmacêutica".
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
BR112018007526A2 (pt) compostos de benzolactama como inibidores de proteína quinase
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
EP4285906A3 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
MX2019001125A (es) Inhibidores de cinasa macrociclica.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
BR112015003859A2 (pt) compostos de pirazolopirimidina como inibidores de quinase
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
CL2014001529A1 (es) Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades.
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
EA201591781A1 (ru) Химические соединения
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
EA201692470A1 (ru) Фармацевтические комбинации
TW201613577A (en) Pharmaceutical combinations
BR112018017067A2 (pt) pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inibidores de pde1
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2015, OBSERVADAS AS CONDICOES LEGAIS